Clinical experience with aripiprazole long-acting injection

2016 ◽  
Vol 33 (S1) ◽  
pp. s243-s244
Author(s):  
M.P. Calvo Rivera ◽  
B. Girela Serrano ◽  
A. Porras Segovia ◽  
L. Gutiérrez Rojas
Keyword(s):  
Clinical Evaluation ◽  
Psychotic Disorders ◽  
Good Health ◽  
Health Condition ◽  
Sf 36 ◽  
Monthly Injection ◽  
Competing Interest ◽  
Long Acting ◽  
And Function

IntroductionAripiprazole long-acting injection is the latest long-acting injectable (LAI) antipsychotic medication released in the market which requires a monthly injection.ObjectivesThe aim of our study is to present our experience in the use of Aripiprazole long-acting injection as maintenance therapy in patients with schizophrenia and other psychotic disorders.MethodologyOur sample consists of 20 patients who started treatment with long acting aripiprazole during the last 6 months of its release. Validated scales for collecting information on sociodemographic, clinical evaluation (CGI scale), quality of life (health questionnaire SF-36) and function (Sheehan Disability Inventory and social relationship scale SBS) were used.ResultsThe health condition of the patients was generally good and 68% reported feeling better than during the last year. Social functioning was adequate (level 1 or 2) in about 70% of the patients. Social, employment and family's disability was mild in 57% of cases, the average stress’ perception was 23% and the average social support perception was 72%. Regarding the clinical evaluation, in comparison to the initiation of the treatment 18% of the patients were slightly better, 45% moderately better and 36% much better.ConclusionA remarkable clinical improvement was observed, maintaining good health, with an acceptable level of functionality. This study shows that the incorporation of long-acting Aripiprazole to the treatment of our sample has been a significant improvement in overall functioning of the patient.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Aripiprazole once-monthly efficacy in patients with schizophrenia. Review

2016 ◽  
Vol 33 (S1) ◽  
pp. S582-S582
Author(s):  
M.F. Molina López ◽  
M.C. Cancino Botello ◽  
A. Peña Serrano ◽  
M.D.L.A. Canseco Navarro
Keyword(s):  
Quality Of Life ◽  
Negative Symptoms ◽  
Partial Agonist ◽  
Emotional Interaction ◽  
Medication Delivery ◽  
Pubmed Database ◽  
Competing Interest ◽  
Long Acting

Introductionlong acting injectable formulations of antipsychotics are a valuable option for patients with schizophrenia, offering continuous medication delivery and stable dosage levels. Aripiprazole once-monthly is the first dopamine partial agonist available in long acting formulation approved in Europe for Schizophrenia with excellent results so far.Aimsto conduct a current review of articles related to the use and efficacy of Aripiprazole once monthly in patients with Schizophrenia.Methodssystematic review of the literature in English using the following keywords: “aripiprazole once-monthly”, “aripiprazole long acting formulation”, “schizophrenia”. PubMed database.ResultsAripiprazole once-monthly (AOM) formulation efficacy has been proven in many studies. The importance of maintaining an oral overlap during 14 days is highlighted in all studies that have been reviewed in order to reach therapeutic level; therefore, it can be used in patients with acute decompensations. Recent studies comparing AOM versus Paliperidone Palmitate once monthly (PP) have shown that patients with AOM had greater clinical improvement and, even though both drugs were well tolerated, when Quality of Life Style Scale was analyzed an important improvement in empathy, sense of purpose, emotional interaction and curiosity in the AOM group was observed.Conclusionslong acting injectable antipsychotics increase long-term adherence treatment and reduce risk of relapse. Because of its unique mechanism of action, Aripiprazole once-monthly improves positive and negative symptoms, giving the patient an opportunity to have a better quality of life.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Psychiatric comorbidities in temporal lobe epilepsy: A case study

2017 ◽  
Vol 41 (S1) ◽  
pp. S474-S474
Author(s):  
L. Jouini ◽  
U. Ouali ◽  
R. Zaouche ◽  
R. Jomli ◽  
Y. Zgueb ◽  
...  
Keyword(s):  
Temporal Lobe Epilepsy ◽  
Temporal Lobe ◽  
Psychotic Disorders ◽  
Psychiatric Symptoms ◽  
Complete Disappearance ◽  
Therapeutic Implications ◽  
Self Harm ◽  
Competing Interest

IntroductionPsychiatric disorders frequently occur in patients with temporal lobe epilepsy (TLE) (70%). This combination further reduces the quality of life of patients as diagnosis is difficult and therapeutic opportunities are often missed.ObjectivesThe aim of this case study is to show the possible association between TLE and psychiatric semiology and its therapeutic implications.MethodsPresentation of the clinical case of Mr BH who experienced psychosis like symptoms, was finally diagnosed with TLE and put under anti-epileptic drugs.ResultsMr BH, aged 22, with no family or personal history, was admitted for aggressive behavior, self-harm, pyromania, and depression. Three years prior to onset of psychiatric symptoms, he reports episodes of pulsatile- left-temporal headache followed by hypertonic movements of the neck. Symptoms were intermittently followed by total amnesia or impaired consciousness. The patient explained symptoms by an inner presence that he called “his twin” and to whom he attributed those behaviors contrary to his will. The discovery of bilateral hippocampal atrophy in magnetic resonance imaging with a normal electroencephalography suggested the diagnosis of TLE with post-ictal psychotic disorders. Patient was put initially on diazepam and olanzapine with partial improvement. Association of valproate led to progressive but then complete disappearance of symptoms and so confirmed our diagnosis.ConclusionsIt is often difficult to attach psychiatric symptoms to epilepsy. The diagnosis should be done on a set of clinical, radiological and electrical arguments.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals Quality of Life among Dialysis Patients in United Arab Emirates

2021 ◽  
Author(s):  
◽  
Abdelbasit Mohamad Abdelhadi Ayoub
Keyword(s):  
Quality Of Life ◽  
United Arab Emirates ◽  
Survey Design ◽  
Community Sample ◽  
Health Condition ◽  
Dialysis Patients ◽  
Cultural Relevancy ◽  
Sf 36 ◽  
Comparative Survey

<p>Background: Quality of Life (QOL) has emerged as an important parameter for evaluating the quality of health care for patients with renal failure. The QOL of dialysis patients in the United Arab Emirates (UAE) has not previously been studied. This research examined the cultural relevancy of two QOL tools and compared the QOL between dialysis patients and a sample from the community in UAE. Method: A descriptive comparative survey design was used to study the QOL of 161 dialysis patients and 350 participants from the community. Dialysis patients completed the SF-36 and the QOL Index dialysis version tool. Participants from the community completed the SF-36 and QOL Index generic version tool. Both samples also completed three open-ended questions about the cultural relevancy of the tools. Analysis using descriptive and inferential statistics was done within and between groups to establish similarities and differences in QOL scores. Open-ended questions were analysed thematically. Results: The overall QOL for dialysis patients was rated lower when self-assessed using the SF-36 compared with the community sample (58.92 vs. 75.02, p = <0.0001). Furthermore, the overall QOL for dialysis patients was rated almost the same when self-assessed using the QOL Index compared with the community sample (77.2 vs. 78.6, p = 0.421). Moreover, the total scores of both tools were higher in the community sample (75.02 vs. 78.6). The comparison between the statistically significant variables for both samples revealed contradictory results with the two tools. The majority of participants considered both tools culturally relevant in general. There were more questions that were not answered by participants in the QOL Index by both samples compared with the SF-36. Conclusion: In the UAE the SF 36 and the QOL Index capture different aspects of quality of life. Clinicians and researchers need to be aware of these differences when using these tools. An effective way of establishing the cultural relevancy of QOL tools involves comparing the QOL of a group with a health condition with a sample from the community, asking the participants about their views of the cultural relevancy of the tools, examining missing data, and asking participants open-ended questions about what they value in life.</p>

Effectiveness of long-acting injectables and clozapine in a real-world setting during the early-stages of psychotic illness

2016 ◽  
Vol 33 (S1) ◽  
pp. S105-S105
Author(s):  
E.G. Ostinelli ◽  
E. Guanella ◽  
S. Cavallotti ◽  
C. Casetta ◽  
A. D’Agostino
Keyword(s):  
Psychotic Disorders ◽  
Pharmacological Intervention ◽  
Psychotic Illness ◽  
Treatment As Usual ◽  
Early Stages ◽  
Hospitalization Rates ◽  
Real World Setting ◽  
The Difference ◽  
Competing Interest ◽  
Long Acting

IntroductionIntervention in the early-stages of psychosis may be able to shape the clinical course; critical period (CP) is best represented by the first 5 years from first admission (FA).ObjectivesTo investigate the effectiveness of pharmacological intervention within and beyond the CP.Aims(1) To compare hospitalization rates of patients stabilized on treatment with LAIs and CLZ. (2) To determine whether treatment with LAIs and CLZ within CP can influence hospitalization rates.MethodsData were retrospectively collected from patients diagnosed with non-affective psychoses with FA between 2000 and 2014; 200 patients were then divided into three groups, according to stabilized treatment regimen during the final year of observation: treatment as usual (TAU), CLZ, LAIs. hospitalization duration (HSPD) and frequency (HSP) were calculated for each group.ResultsDespite a major severity before assignment to either CLZ or LAIs treatment, HSPD and HSP in both groups shifted below those observed for the TAU arm. Patients who began treatment with LAIs within the CP showed a highly significant decrease of both HSPD and HSP (respectively 17.4 ± 18 vs. 2.6 ± 8.2; Z = −2.856; P < 0.005 and 1.1 ± 0.8 vs. 0.2 ± 0.5; Z = −3.115; P < 0.005). No significant changes in hospitalization rates were observed for subjects who began treatment with LAIs after the CP.ConclusionsOur study confirms that treatment with either CLZ or LAIs significantly impacts the course of psychotic disorders. The data seem to suggest that LAIs and CLZ should be considered more effective than conventional oral antipsychotics in the early-stages of psychotic illness. The difference among treatments tends to wane beyond the CP, especially for LAIs.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals Durability of Stretta Radiofrequency Treatment for GERD: Results of an 8-Year Follow-Up

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Luca Dughera ◽  
Gianluca Rotondano ◽  
Maria De Cento ◽  
Paola Cassolino ◽  
Fabio Cisarò
Keyword(s):  
Quality Of Life ◽  
Clinical Evaluation ◽  
Upper Endoscopy ◽  
Follow Up Study ◽  
Energy Delivery ◽  
Sf 36 ◽  
Significant Amelioration ◽  
Baseline Values

From June 2002 to March 2013 26 patients that underwent Stretta procedure (16 females, 10 males) reached to date an eight-year follow-up. Primary end point of the study was to verify the durability of the procedure at this time. All patients underwent clinical evaluation by upper endoscopy, oesophageal pressure, and pH studies. For each patient 8-year data were compared to those recorded at baseline and at 4 years. There was a significant decrease in both heartburn and GERD HRQL scores at 4 years (P=0.001) and at 8 years (P=0.003) as well as a significant increase of QoL scores at each control time (mental SF-36 and physical SF-36,P=0.001). After 4 and 8 years, 21 patients (80.7%,P=0.0001) and 20 patients (76.9%,P=0.0001) were completely off PPIs. Median LES pressure did not show significant amelioration at 4 and 8 years and mean oesophageal acid exposure significantly improved at 4 years (P=0.001) but returned to baseline values after 8 years. This further follow-up study of ours from four to eight years confirms that RF energy delivery for GERD provides durable improvement in symptoms and in quality of life and reduces antireflux drugs consumption.

scholarly journals Changes in attitude towards LAI antipsychotic maintenance treatment: A two-year follow-up study

2018 ◽  
Vol 53 ◽  
pp. 58-65 ◽  
Author(s):  
Francesco Pietrini ◽  
Giulio D’Anna ◽  
Lorenzo Tatini ◽  
Gabriela Alina Talamba ◽  
Costanza Andrisano ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Maintenance Treatment ◽  
Subjective Experience ◽  
Open Label ◽  
Sf 36 ◽  
Patient Reported ◽  
Long Acting ◽  
Prospective Longitudinal

AbstractBackground:To present real-world evidence on the effects of switching from oral to long-acting injectable (LAI) antipsychotic maintenance treatment (AMT) in a sample of clinically stable patients with schizophrenia, with regard to subjective experience of treatment, attitude towards drug and quality of life.Methods:50 clinically stable adult schizophrenic outpatients were recruited. At the time of enrolment (T0), all patients were under a stabilized therapy with a single oral second-generation antipsychotic (SGA) and were switched to the equivalent maintenance regimen with the long-acting formulation of the same antipsychotic. 43 patients completed the 24-month prospective, longitudinal, open-label, observational study. Participants were assessed at baseline (T0), after 12 (T1) and 24 months (T2), using psychometric scales (PANSS, YMRS and MDRS) and patient-reported outcome measures (SWN-K, DAI-10 and SF-36).Results:The switch to LAI-AMT was associated with a significant clinical improvement at T1 and T2 compared to baseline (T0). All of the psychometric indexes, as well as patients’ subjective experience of treatment (SWN-K), and quality of life (SF-36) showed a significant improvement after one year of LAI-AMT, with stable results after two years. Patients’ attitude towards drug (DAI-10) increased throughout the follow-up period, with a further improvement during the second year.Conclusions:The switch to LAI-AMT may help to address the subjective core of an optimal recovery in stabilized schizophrenic patients. A sustained improvement in patients’ attitude towards drug may help to achieve patient’s compliance. The size of this study needs to be expanded to produce more solid and generalizable results.

Effectiveness of long-acting aripiprazole in schizoaffective disorders: A naturalistic longitudinal study

2017 ◽  
Vol 41 (S1) ◽  
pp. S757-S757
Author(s):  
A. Nivoli ◽  
M. Antonioli ◽  
L. Folini ◽  
L. Floris ◽  
G. Meli ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Schizoaffective Disorder ◽  
Rating Scale ◽  
Psychiatric Clinic ◽  
Significant Difference ◽  
Sample Test ◽  
Competing Interest ◽  
Long Acting ◽  
Over Time

IntroductionIntramuscular paliperidone palmitate (PP) is a long-acting, atypical anti-psychotic for once monthly intramuscular (IM) administration in the treatment of patients with schizophrenia.ObjectiveTo study the effectiveness (efficacy and quality of life) of ARP in the maintenance treatment of schizoaffective disorder.MethodsA non-randomized, prospective naturalistic study was performed in out-patients with schizoaffective disorder unsuccessfully treated with oral anti-psychotics. Efficacy of ARP over time was evaluated by using brief psychiatric rating scale (BPRS 24-items), quality of life was evaluated by using QL-Index, both at T0 and at most recent visit (T1). Data were analyzed with Student's t-tests and Pearson correlations (α value, two tailed). Paired t-test was applied for BPRS and for Ql-Index total scores (T0–T1).ResultsData were available for 8 outpatients consecutively prescribed ARP and naturalistically treated attending at the psychiatric clinic, university of Sassari. Mean time on ARP treatment was 207.14 days (sd 137.2). BPRS mean total score at T0 was 57 (sd 13.2) and at T1 was 39.7 (sd 10.8). QL-Index mean total score was at T0 5.43 (sd 1.6) and at T1 7.14 (sd 2.7). Paired sample test showed a statistically significant difference in decreasing symptoms at BPRS over time (P = 0.001) and QL-Index total score (P = 0.023). The analyses showed a significant improving at the following BPRS sub-items: anxiety (P = 0.005), mood elevation (P = 0.014) conceptual disorganization (P = 0.048), emotional withdrawal (P = 0.05), tension (P = 0.02) and distractibility (P = 0.03).Disclosure of interestThe authors have not supplied their declaration of competing interest.

Hemodialysis and peritoneal dialysis—health-related quality of life: systematic review plus meta-analysis

2021 ◽  
pp. bmjspcare-2021-003182
Author(s):  
Samira Raoofi ◽  
Fatemeh Pashazadeh Kan ◽  
Sima Rafiei ◽  
Zahra Hoseinipalangi ◽  
Sepide Rezaei ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Short Form ◽  
Meta Analysis ◽  
Health Condition ◽  
Factors Affecting ◽  
Sf 36 ◽  
Wide Range ◽  
Health Related ◽  
The Mean

BackgroundPatients with end-stage renal disease undergoing haemodialysis experience a variety of stressors leading to decreased level of quality of life (QoL). Thus, in this study, we aimed to review the current literature and identify factors affecting the health-related QoL (HRQoL) in these patients.MethodsA total of 147 studies were extracted from databases of Web of Science, PubMed, Scopus, Google Scholar, and Embase published between January 2000 and December 2020. Data were analysed using R software and results were reported with reference to Preferred Reporting Items for Systematic Reviews and Meta-Analyses standards.ResultsA total of 623 728 patients undergoing dialysis participated in 147 studies in which QoL was assessed by means of two valid questionnaires, including Short-Form 36 (SF-36) and Kidney Disease Quality of Life (KDQOL)-short form V.1.3. Total HRQoL score for patients undergoing dialysis measured by KDQOL was 64.25 (95% CI 55.67 to 72.82). Based on SF-36, the mean score of mental health items was higher than the mean score of physical health condition. Furthermore, meta-regression based on the geographical place of residence revealed that the highest QoL in patients was observed in Japan, 66.96 (95% CI 63.65 to 70.28) and Brazil, 58.03 (95% CI 53.45 to 62.6).ConclusionStudies conducted on HRQoL among patients undergoing dialysis recommend useful strategies to clinicians, letting them assess patients’ QoL in terms of a wide range of physical, mental and environmental aspects.

Treatment with intramuscular paliperidone palmitate in schizoaffective disorder

2016 ◽  
Vol 33 (S1) ◽  
pp. S581-S581
Author(s):  
L. Maroto Martin ◽  
P. Hervías Higueras
Keyword(s):  
Schizoaffective Disorder ◽  
Complex Disease ◽  
Psychotic Disorders ◽  
Paliperidone Palmitate ◽  
Valuable Treatment ◽  
History Of ◽  
Competing Interest ◽  
One Year ◽  
Long Acting ◽  
Monthly Dose

IntroductionInjectable formulations of long acting antipsychotic are a valuable treatment option for patients with psychotic disorders. Schizoaffective Disorder (SAD) is a complex disease; the optimal treatment is not well established yet.ObjectiveAnswer the question about the effectiveness offered by intramuscular Paliperidone Palmitate in SAD versus other injectable antipsychotics. Keywords: schizoaffective disorder; paliperidone palmitate injection.MethodsA case report of a 35-year-old male diagnosed with Schizoaffective Disorder six years ago and with personal history of multiple manic decompensation after treatment discontinuation. Throughout his life he has been treated with intramuscular Risperidone 87.5 mg (50 + 37.5) every 14 days, Olanzapine flas 20 mg/day, Risperidone flas 3 mg, Amisulpride 600 mg/day, Valproic acid 1500 mg/day Clonazepam 2 mg/day and Lormetazepam 1 mg. In the last admission one year ago, he started treatment with intramuscular paliperidone palmitate up to 200 mg a month. Currently he receives a monthly dose of 100 mg and concomitant lithium 800 mg/day.DiscussionThe use of intramuscular paliperidone palmitate in SAD and its effectiveness against other injectable antipsychotic is discussed.ConclusionsThe use of intramuscular paliperidone palmitate appears to constitute an employment opportunity in the treatment of intramuscular maintenance in SAD. It could be effective in stabilizing episodes of acute exacerbation and remissions of psychotic, manic and depressive symptoms.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Establishing remission and good clinical functioning in schizophrenia: Predictors of best outcome with long-term risperidone long-acting injectable treatment

2010 ◽  
Vol 25 (4) ◽  
pp. 220-229 ◽  
Author(s):  
M. Lambert ◽  
T. De Marinis ◽  
J. Pfeil ◽  
D. Naber ◽  
A. Schreiner
Keyword(s):  
Quality Of Life ◽  
Symptom Severity ◽  
Psychotic Disorders ◽  
Country Of Origin ◽  
Open Label ◽  
Positive Treatment ◽  
Symptomatic Remission ◽  
Long Acting ◽  
Psychoactive Medications

AbstractObjectiveTo measure symptomatic and functional remission in patients treated with risperidone long-acting injectable (RLAI).MethodsStable patients with psychotic disorders requiring medication change were switched to open-label RLAI in the switch to risperidone microspheres (StoRMi) trial. In this post-hoc analysis of the trial extension, follow-up was ≤18 months. Symptomatic remission was based on improvement in positive and negative syndrome scale (PANSS) scores and global remission (best outcome) was based on symptomatic remission, functional level, and mental-health quality of life. Predictive factors were evaluated.ResultsAmong 529 patients from seven European countries, mean participation duration was 358.7 ± 232.4 days, with 18 months completed by 39.9% of patients. Symptomatic remission lasting ≥6 months occurred at some point during treatment in 33% of patients; predictors included comorbid disease, country, baseline symptom severity, baseline functioning, type of antipsychotic before switching, and duration of untreated psychosis. Best outcome occurred in 21% of patients; predictors included baseline symptom severity, baseline functioning, country, schizophrenia type, and early positive treatment course.ConclusionsOne in three patients with stable schizophrenia switching to RLAI experienced symptomatic remission, with combined symptomatic, functional, and quality-of-life remission in one in five patients. Symptomatic remission was predicted by better baseline symptom severity and country of origin, with a significantly greater likelihood of remission occurring among patients in Estonia/Slovenia compared with Portugal. Relapse was predicted by higher mode doses of RLAI, additional use of psychoactive medications, male gender, and country of origin, with relapse occurring most frequently in France and least frequently in Portugal. RLAI dose, additional use of psychoactive medications, and country of origin predicted best outcome, with best outcome occurring most frequently in Estonia/Slovenia and least frequently in Portugal.

Sign in / Sign up

Export Citation Format

Share Document